HEALTH Minister Greg Hunt yesterday announced the Pharmaceutical Benefits Scheme listing of "crucial medicines" to treat cancer, motor neurone disease and Parkinson's disease.
The PBS additions, all effective from 01 Apr 2019, include $19m to broaden the listing of Adcetris (brentuximab vedotin) to include treatment of cutaneous T-cell lymphomas; the first time PBS listing of Xadago (safinamide) for the treatment of Parkinson's disease; and Teglutik (riluzole) for the treatment of amyotrophic lateral sclerosis.
More at health.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Mar 19
